BioLife Solutions Inc (BLFS)

[techisbest]

A split isn't dilution. Did they talk about dilution in addition to the split?

I thought they were just doing the reverse split to make it possible to be listed on a major exchange.

You get 1 share for every 14 you own. And the price per share is multiplied by 14. No change in value.

BLFS is now BLFSD (signifying the split).

What can happen is that the number of authorized shares does not change. So now there is more room to authorize new shares.

But unless they do that there is no dilution.

Or are you referring to this:

"On December 16, 2013, BioLife announced that its two debt holders have agreed to convert the Company's entire secured debt of approximately $14 million in principal and accrued interest into equity in connection with the Company's next equity financing."

There is this opinion:
http://seekingalpha.com/article/1956851-biolife-solutions-uplisting-debt-deal-provide-overlooked-opportunity?source=yahoo

"More importantly, BioLife has also addressed its debt. The company's balance sheet has long been a source of concern - on the surface, the company is on the brink of insolvency. As its latest 10-Q shows, the company ended Q3 2013 with just $79,287 in cash and over $10.6 million in debt, plus $3.3 million in accrued interest. What investors can't forget is that BioLife's creditors are also the company's largest investors, with a combined stake of around 47% - they have a vested interest in ensuring that the company avoids insolvency given that their equity stake in BioLife outweighs their debt holdings.

On December 26, BioLife inked an agreement with creditors Thomas Girschweiler and Walter Villiger to restructure its balance sheet. Both Girschweiler and Villiger have agreed to exchange all principal and accrued interest on BioLife's debt into equity in conjunction with the company's "next equity financing." Although this will lead to dilution for existing investors, we note that the single largest shareholder group is the company's board of directors and management team. Michael Rice, CEO, alone owns over 9% of the company, and together BioLife's management team and board of directors own 36.9% of the company as of December 16 on a diluted basis. If these shareholders are amenable to seeing their stakes diluted in order to clean up BioLife's balance sheet, then we are as well.

It's almost important to note that BioLife's board and management team did not cash out in excess as BioLife moved closer to $2 late last year. The table below compares the stakes of the officers and directors named in BioLife's Schedule 14C, filed on December 27, 2013, and BioLife's latest proxy statement, filed on April 30, 2013."